Instrument Inactif

Communiqués Actelion London S.E.

Actions

CH0010532478

Recherche biotechnologique et médicale

Communiqués

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
15/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU
14/06/17	Actelion : announces changes to its executive team upon completion of the transaction with Johnson & Johnson	GL
09/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	GL
09/06/17	Actelion : Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017	GL
08/06/17	Actelion : provides an update on the Phase III IMPACT program with cadazolid in CDAD	GL
22/05/17	Actelion : provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia	GL
15/05/17	Actelion : announces changes to its executive team upon completion of the transaction with Johnson & Johnson	GL
27/04/17	Actelion : Publication of the definitive notice of the end result of Actelion tender offer	GL
24/04/17	Actelion : Publication of the provisional notice of the end result of Actelion tender offer	GL
10/04/17	Actelion : amends its financial reporting schedule	GL
05/04/17	Actelion : Annual General Meeting of Shareholders 2017	GL
31/03/17	Actelion : Johnson & Johnson publishes interim result for Actelion tender offer and declares the tender offer successful	GL
15/03/17	Actelion : issues invitation to 2017 Annual General Meeting of Shareholders	GL
07/03/17	Actelion : is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL	GL
02/03/17	Actelion : obtains "Epoprostenol ACT" label extension for pediatric PAH patients in Japan	GL
16/02/17	Actelion : Johnson & Johnson publishes prospectus for Actelion tender offer	GL
14/02/17	Actelion : announces excellent financial results for 2016	GL
10/02/17	Actelion : concludes second line share repurchase program	GL
26/01/17	CORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW R&D COMPANY	GL
26/01/17	Actelion : JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW R&D COMPANY	GL
23/01/17	Actelion : announces results of the MAESTRO study with macitentan in patients with pulmonary arterial hypertension due to Eisenmenger Syndrome	GL